Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study - 18/04/17
Abstract |
Background |
Hidradenitis suppurativa (HS) is often associated with inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis). However, the prevalence of IBD in HS patients is unknown.
Objective |
To determine the prevalence of IBD in HS patients, and determine if patients with HS and IBD have a distinct HS phenotype.
Methods |
For this multicenter, cross-sectional study, HS patients were asked during their first consultation if they had IBD. The diagnosis of IBD was checked in the medical files, and clinical characteristics were collected.
Results |
IBD had a prevalence of 3.3% (95% CI 2.3-4.4) in 1076 HS patients. The prevalence of Crohn's disease was 2.5% (95% CI 1.6-3.4) and the prevalence of ulcerative colitis was 0.8% (95% CI 0.3-1.4). HS-IBD patients were less frequently obese (13.9% vs 31.2%, P = .04) than HS-only patients, but there were no differences in gender, family history of HS, disease severity, body areas affected by HS, or smoking status.
Limitations |
The prevalence might be underestimated since HS patients might still develop IBD.
Conclusion |
The prevalence of IBD in HS patients (3.3%) is 4-8 times higher than the prevalence in the general northern European population (0.41%-0.74%), however HS-IBD patients do not have a distinct HS phenotype.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, Crohn's disease, ulcerative colitis, comorbidity, epidemiology, risk factor, prevalence, association
Abbreviations used : BMI, CD, CI, HS, HS-IBD, IQR, IBD, NOD2, UC
Plan
| Drs Benhadou and Koldijk contributed equally to this work. |
|
| Funding sources: None. |
|
| Disclosure: B Horváth performed investigator-initiated studies of Janssen Cilag BV (The Netherlands) and AbbVie Inc; she received an unrestricted educational grant from AbbVie Netherlands (The Netherlands). Further, she has acted as a consultant for AbbVie and Janssen-Cilag. EP Prens has acted as a consultant for AbbVie, Amgen, Astra-Zeneca, Baxter, Eli Lilly, Idera, Galderma, Janssen-Cilag, Novartis, NTRC, and Pfizer and has received investigator-initiated research grants from Pfizer, Janssen-Cilag, and AbbVie. J Boer is on the advisory board of AbbVie Inc. F Benhadou has received honoraria from AbbVie Inc for participating in the advisory board. HH van der Zee has received honoraria from AbbVie Inc for participating in the advisory board. |
Vol 76 - N° 1
P. 49-53 - janvier 2017 Retour au numéro
Article précédent
- Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study
- Miri Kim, Kwang Hyun Choi, Se Won Hwang, Young Bok Lee, Hyun Jeong Park, Jung Min Bae
- The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study
- George Denny, Milan J. Anadkat
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?